Phase I/II Study of Plerixafor and Clofarabine in Previously Untreated Older (>/=60 Years) Adult Patients With Acute Myelogenous Leukemia (AML) With Two or More Unfavorable Prognostic Factors for Whom Standard Induction Chemotherapy is Unlikely to be of Benefit is a PHASE1 clinical asset sponsored by M.D. Anderson Cancer Center in Acute Myelogenous Leukemia. SEO and diligence focus: Plerixafor, Clofarabine, endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.